XML 54 R42.htm IDEA: XBRL DOCUMENT v3.22.4
DESCRIPTION OF BUSINESS (Details) - USD ($)
$ in Thousands, shares in Millions
1 Months Ended 12 Months Ended
Sep. 30, 2016
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Variable Interest Entity [Line Items]        
Cash, cash equivalents, and marketable securities   $ 166,900    
Accumulated deficit   336,141 $ 316,257  
Negative cash flows from operating activities incurred   $ (24,895) $ 68,878 $ 30,837
Viventia Bio Inc.        
Variable Interest Entity [Line Items]        
Shares of common stock issued to the selling shareholders (in shares) 4.0      
Percentage of voting interests acquired 19.90%      
Period during which quarterly earn-outs are payable after date of net sales 15 years      
Period in which acquiree is to use commercially reasonable efforts to achieve marketing authorizations 7 years      
Viventia Bio Inc. | Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone        
Variable Interest Entity [Line Items]        
Percentage of net sales of quarterly earn-out payments during earn-out periods 2.00%      
Viventia Bio Inc. | Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone | United States        
Variable Interest Entity [Line Items]        
One-time milestone payment upon first sale of product $ 12,500      
Viventia Bio Inc. | Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone | Europe        
Variable Interest Entity [Line Items]        
One-time milestone payment upon first sale of product 7,000      
Viventia Bio Inc. | Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone | Japan        
Variable Interest Entity [Line Items]        
One-time milestone payment upon first sale of product $ 3,000